Early Dupilumab in Pediatric EoE Tied to Lower Incident Asthma

A retrospective study presented at the ACAAI 2026 meeting suggests that children treated with dupilumab for eosinophilic esophagitis before age 6 have a significantly lower incidence of asthma later in life. The findings indicate that early intervention in the T2 inflammatory pathway may prevent the development of subsequent atopic conditions.
Why it matters
This research could shift pediatric treatment protocols for atopic diseases, potentially reducing the long-term burden of asthma in children with EoE.
Children with eosinophilic esophagitis (EoE) treated with dupilumab before age 6 years had about half the incidence of asthma 3.5 years later compared with matched children who never received the biologic, according to a retrospective cohort study presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, held November 12 to 16, 2026.1
Dupilumab, a monoclonal antibody inhibiting interleukin 4 and interleukin 13 signaling, is the only FDA-approved biologic for EoE and is approved for patients as young as 1 year, but its asthma indication begins at age 6 years.1,2 Kayla J. Steinberger, MD, PhD, resident physician, Department of Pediatrics at West Virginia University, used this gap between approved ages to assess whether dupilumab given for EoE early in childhood was associated with later asthma.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in